サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1390623

ヒトマイクロバイオーム市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Human Microbiome Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 145 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ヒトマイクロバイオーム市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年11月24日
発行: IMARC
ページ情報: 英文 145 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界のヒトマイクロバイオーム市場規模は2022年に6億7,910万米ドルに達しました。今後、IMARC Groupは、市場は2028年までに20億5,850万米ドルに達し、2022年から2028年の間に20.30%の成長率（CAGR）を示すと予測しています。

ヒトマイクロバイオームとは、ヒトの遺伝的肖像（メタゲノム）に見られる様々な微生物内に存在する遺伝子を指します。細菌、真菌、原生動物、非生物ウイルス、多数の単細胞生物など、様々な微生物から構成されています。これらの微生物はヒトの生理機能に影響を与え、代謝機能や免疫機能の向上や障害に寄与しています。これらの微生物はヒトの組織に存在し、医学の進歩や分析技術のために研究されています。マイクロバイオームは、糖尿病、肥満、がん、代謝性疾患、胃腸疾患、神経疾患、中枢神経系疾患、自己免疫疾患などの様々な疾患に対するプロバイオティクス、プレバイオティクス、医薬品、診断・治療システムに利用されています。

ヒトマイクロバイオーム市場の動向：

微生物異常による慢性的な生活習慣病や感染症が世界中で蔓延していることが、市場成長を促進する主な要因の一つです。さらに、このような病気にかかりやすい老年人口が増加していることも、市場の成長を後押ししています。同市場の成長は、有効性を高めたヒトマイクロバイオーム治療薬の開発が重視されるようになっていることにも起因しています。例えば、ヒト腸内マイクロバイオームは、様々な胃腸疾患の効果的な治療のために特定の組み合わせで開発されています。これに伴い、コロナウイルス（COVID-19）の大流行も市場の成長を後押ししています。研究者は、感染の重症度を分析し、適切な治療薬やワクチンを開発するために、肺マイクロバイオームを幅広く研究しています。さらに、標的特異的なマイクロバイオームベースの治療法の開発など、さまざまな進歩も市場の成長を後押ししています。その他の要因としては、広範な研究開発（R&D）活動、特に新興経済諸国における製薬産業の著しい成長などが挙げられ、市場の成長を後押しすると予想されます。

本レポートで扱う主な質問

  • 世界のヒトマイクロバイオーム市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19が世界のヒトマイクロバイオーム市場に与えた影響は？
  • 主要な地域市場は？
  • 製品別の市場内訳は？
  • 用途別の市場内訳は？
  • 疾患タイプ別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界のヒトマイクロバイオーム市場の構造と主要プレーヤーは？
  • 業界における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 ヒトマイクロバイオームの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • プロバイオティクス
    • 市場動向
    • 市場予測
  • プレバイオティクス
    • 市場動向
    • 市場予測
  • 診断テスト
    • 市場動向
    • 市場予測
  • 医薬品
    • 市場動向
    • 市場予測
  • 医療食品
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：用途別

  • 治療
    • 市場動向
    • 市場予測
  • 診断
    • 市場動向
    • 市場予測

第8章 市場内訳：疾患タイプ別

  • 肥満症
    • 市場動向
    • 市場予測
  • 糖尿病
    • 市場動向
    • 市場予測
  • 自己免疫疾患
    • 市場動向
    • 市場予測
  • がん
    • 市場動向
    • 市場予測
  • 消化器疾患
    • 市場動向
    • 市場予測
  • 中枢神経系疾患
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • 4D pharma plc
    • Atlas Biomed Group Limited
    • BIOHM
    • BiomX
    • Bione
    • DayTwo Inc.
    • ENTEROME
    • Ferring B.V.
    • Finch Therapeutics
    • Second Genome Inc.
    • SynBioBeta LLC
    • Synthetic Biologics Inc.
    • Vedanta Biosciences Inc.
    • Viome Inc.
図表

List of Figures

  • Figure 1: Global: Human Microbiome Market: Major Drivers and Challenges
  • Figure 2: Global: Human Microbiome Market: Sales Value (in Million US$), 2017-2022
  • Figure 3: Global: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 4: Global: Human Microbiome Market: Breakup by Product (in %), 2022
  • Figure 5: Global: Human Microbiome Market: Breakup by Application (in %), 2022
  • Figure 6: Global: Human Microbiome Market: Breakup by Disease Type (in %), 2022
  • Figure 7: Global: Human Microbiome Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Human Microbiome (Probiotics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Human Microbiome (Probiotics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Human Microbiome (Prebiotics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Human Microbiome (Prebiotics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Human Microbiome (Diagnostic Tests) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Human Microbiome (Diagnostic Tests) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Human Microbiome (Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Human Microbiome (Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Human Microbiome (Medical Food) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Human Microbiome (Medical Food) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Human Microbiome (Other Products) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Human Microbiome (Other Products) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Human Microbiome (Therapeutics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Human Microbiome (Therapeutics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Human Microbiome (Diagnostics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Human Microbiome (Diagnostics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Human Microbiome (Obesity) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Human Microbiome (Obesity) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Human Microbiome (Diabetes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Human Microbiome (Diabetes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Human Microbiome (Autoimmune Disorders) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Human Microbiome (Autoimmune Disorders) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Human Microbiome (Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Human Microbiome (Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Human Microbiome (Gastrointestinal Disorders) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Human Microbiome (Gastrointestinal Disorders) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Global: Human Microbiome (Central Nervous System Disorders) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Global: Human Microbiome (Central Nervous System Disorders) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Global: Human Microbiome (Other Disease Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Global: Human Microbiome (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: North America: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: North America: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: United States: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: United States: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Canada: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Canada: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Asia-Pacific: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Asia-Pacific: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: China: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: China: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Japan: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Japan: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: India: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: India: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: South Korea: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: South Korea: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Australia: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Australia: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Indonesia: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Indonesia: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Others: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Others: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Europe: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Europe: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Germany: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Germany: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: France: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: France: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: United Kingdom: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: United Kingdom: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Italy: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Italy: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Spain: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Spain: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Russia: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Russia: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Others: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Others: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Latin America: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Latin America: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Brazil: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Brazil: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Mexico: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Mexico: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Others: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 83: Others: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 84: Middle East and Africa: Human Microbiome Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 85: Middle East and Africa: Human Microbiome Market: Breakup by Country (in %), 2022
  • Figure 86: Middle East and Africa: Human Microbiome Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Global: Human Microbiome Industry: SWOT Analysis
  • Figure 88: Global: Human Microbiome Industry: Value Chain Analysis
  • Figure 89: Global: Human Microbiome Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Human Microbiome Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Human Microbiome Market Forecast: Breakup by Product (in Million US$), 2023-2028
  • Table 3: Global: Human Microbiome Market Forecast: Breakup by Application (in Million US$), 2023-2028
  • Table 4: Global: Human Microbiome Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
  • Table 5: Global: Human Microbiome Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Human Microbiome Market: Competitive Structure
  • Table 7: Global: Human Microbiome Market: Key Players
目次
Product Code: SR112023A4420

Abstract

The global human microbiome market size reached US$ 679.1 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 2,058.5 Million by 2028, exhibiting a growth rate (CAGR) of 20.30% during 2022-2028.

The human microbiome refers to the genes present inside various microorganisms found in the genetic portrait, or metagenome, of humans. It consists of various microorganisms, such as bacteria, fungi, protozoans, non-living viruses and numerous single-celled organisms. These organisms impact human physiology and contribute to the enhancement or impairment of metabolic and immune functions. They are found in the human tissues and are studied for medical advancements and analytical techniques. Microbiomes are utilized in probiotics, prebiotics, pharmaceutical drugs and diagnostic and therapeutic systems for various ailments, such as diabetes, obesity, cancer and metabolic, gastrointestinal, neurological, central nervous system and autoimmune disorders.

Human Microbiome Market Trends:

The increasing prevalence of chronic lifestyle diseases and infections due to microbial dysbiosis across the globe is one of the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. The growth of the market can also be attributed to the increasing emphasis on the development of human microbiome therapeutics with enhanced efficacy. For instance, human gut microbiomes are being developed in specific combinations for the effective treatment of various gastrointestinal ailments. In line with this, the onset of the coronavirus (COVID-19) pandemic is also providing a thrust to the market growth. Researchers are extensively studying the lung microbiomes to analyze the severity of the infections and develop appropriate therapeutics and vaccines. Additionally, various advancements, such as the development of target-specific microbiome-based therapies, are also favoring the growth of the market. Other factors, including extensive research and development (R&D) activities, along with significant growth in the pharmaceutical industry, especially in the developing economies, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global human microbiome market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, application and disease type.

Breakup by Product:

Probiotics

Prebiotics

Diagnostic Tests

Drugs

Medical Food

Others

Breakup by Application:

Therapeutics

Diagnostics

Breakup by Disease Type:

Obesity

Diabetes

Autoimmune Disorders

Cancer

Gastrointestinal Disorders

Central Nervous System Disorders

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 4D pharma plc, Atlas Biomed Group Limited, BIOHM, BiomX, Bione, DayTwo Inc., ENTEROME, Ferring B.V., Finch Therapeutics, Second Genome Inc., SynBioBeta LLC, Synthetic Biologics Inc., Vedanta Biosciences Inc. and Viome Inc.

Key Questions Answered in This Report:

  • How has the global human microbiome market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global human microbiome market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the disease type?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global human microbiome market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Human Microbiome Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Probiotics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Prebiotics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Diagnostic Tests
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Drugs
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Medical Food
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Therapeutics
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Diagnostics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Disease Type

  • 8.1 Obesity
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diabetes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Autoimmune Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Gastrointestinal Disorders
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Central Nervous System Disorders
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 4D pharma plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Atlas Biomed Group Limited
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 BIOHM
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 BiomX
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Bione
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 DayTwo Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 ENTEROME
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Ferring B.V.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Finch Therapeutics
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Second Genome Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 SynBioBeta LLC
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Synthetic Biologics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
    • 14.3.13 Vedanta Biosciences Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
    • 14.3.14 Viome Inc.
      • 14.3.14.1 Company Overview
      • 14.3.14.2 Product Portfolio